Oral pan-AMPK activator acquired from Swedish biotech Betagenon. AMPK is the energy sensor; activating it mimics exercise and fasting, increasing metabolic rate.
Phase 1b complete (Jun 2026); Phase 2 planned. From Amplifier Therapeutics.
Updated 18 Jun 2026Checked 10 Oct0 updates this week
AMPK activates when cellular energy is low (as during exercise or fasting), triggering cells to burn fuel and suppress growth and repair pathways.
ATX-304 activates AMPK outside the brain, raising the rate cells burn glucose and fat, increasing resting metabolism.
AMPK activation works in the periphery, raising metabolism without brain activity, offering a complementary approach to GLP-1s.
| Spec | ATX-304 |
|---|---|
| Target mechanism | Pan-AMPK network activatorR (reported) |
| Route of administration | OralR (reported) |
| Phase 1b liver fat reduction | Statistically significant reduction at sub-weight-loss dosesR (reported) |
| Visceral adipose tissue | Statistically significant reduction (Phase 1b)R (reported) |
| Resting metabolic rate | 8% increase (Phase 1b)R (reported) |
| Phase 1b triglyceride improvement | Statistically significant improvementR (reported) |
R reported by the company
| Spec | ATX-304 | Rubedo Life Sciences RLS-1496 |
|---|---|---|
| Target mechanism | Pan-AMPK network activatorR (reported) | GPX4 modulation in senescent cellsR (reported) |
| Route of administration | OralR (reported) | TopicalR (reported) |
R reported by the company
Cambrian Bio
Group of aging biotechs, rapamycin-like drugs
New York company founded by James Peyer that starts and funds a group of small biotechs, each attacking one cause of aging through a specific disease, such as better versions of the drug rapamycin.
